"You can't keep a good man (or woman) down"

Journal of Invasive Cardiology

Volumn 18, Issue 3, 2006, Pages 109-110

  Chhatriwalla, Adnan K ^a   Bhatt, Deepak L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTERY CATHETER; BED REST; BLEEDING; CLINICAL PROTOCOL; COMPRESSION; COST MINIMIZATION ANALYSIS; FALSE ANEURYSM; FEMORAL ARTERY; HEALTH CARE COST; HEART CATHETERIZATION; HEMATOMA; HEMOSTASIS; HOSPITALIZATION; MORBIDITY; NOTE; PRACTICE GUIDELINE; PULSE WAVE; SURGICAL EQUIPMENT; TREATMENT DURATION; VASCULAR ACCESS;

CORONARY ANGIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMANS; INCIDENCE; MALE; SEX DISTRIBUTION; VASCULAR DISEASES;

EID: 33645887826     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Note

References (18)

1. Babu SC, Piccorelli GO, Shah PM, et al. Incidence and results of arterial complications among 16,350 patients undergoing cardiac catheterization. J Vasc Surg 1989;10:113-116.
2. Baim DS, Knopf WD, Hinohara T, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate aNd discharge (STAND I and STAND II) trials. Am J Cardiol 2000;85:864-869.
3. Kapadia SR, Raymond R, Knopf W, et al. The 6Fr Angio-Seal arterial closure device: Results from a multimember prospective registry. Am J Cardiol 2001;87:789-791, A788.
4. SEAL Trial Study Team. Assessment of the safety and efficacy of the DUETT vascular hemostasis device: Final results of the safe and effective vascular hemostasis (SEAL) trial. Am Heart J 2002;143:612-619.
5. Bhatt DL, Raymond RE, Feldman T, et al. Successful "preclosure" of 7Fr and 8Fr femoral arteriotomies with a 6Fr suturebased device (the Multicenter Interventional Closer Registry). Am J Cardiol 2002; 89:777-779.
6. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis. JAMA 2004;291:350-357.
7. Gall S, Tarique A, Natarajan A, Zaman AG. Rapid Ambulation after coronary angiography via femorral artery access: A prospective study of 1000 patients. J Invasive Cardiol 2006;18:106-108.
8. Pollard SD, Munks K, Wales C, et al. Position and Mobilisation Post-Angiography Study (PAMPAS): A comparison of 4.5 hours and 2.5 hours bed rest. Heart 2003;89:447-448.
9. Wood RA, Lewis BK, Harber DR, et al. Early ambulation following 6 French diagnostic left heart catheterization: A prospective randomized trial. Cathet Cardiovasc Diagn 1997;42:8-10.
10. Lim R, Anderson H, Walters MI, et al. Femoral complications and bed rest duration after coronary arteriography. Am J Cardiol 1997;80:222-223.
11. Kern MJ, Cohen M, Talley JD, et al. Early ambulation after 5 French diagnostic cardiac catheterization: Results of a multicenter trial. J Am Coll Cardiol 1990;15:1475-1483
12. Simon A, Bumgarner B, Clark K, et al. Manual versus mechanical compression for femoral artery hemostasis after cardiac catheterization. Am J Crit Care 1998;7:308-313.
13. Chiu JH, Bhatt DL, Ziada KM, et al. Impact of female sex on outcome after percutaneous coronary intervention. Am Heart J 2004;148:998-1002.
14. Perings SM, Kelm M, Jax T, et al. A prospective study on incidence and risk factors of arteriovenous fistulae following transfemoral cardiac catheterization. Int J Cardiol 2003;88:223-228.
15. Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: Implications for risk stratification and treatment. J Am Coll Cardiol 2002; 40:291-297.
16. Knight CG, Healy DA, Thomas RL. Femoral artery pseudoaneurysms: risk factors, prevalence, and treatment options. Ann Vasc Surg 2003;17:503-508.
17. Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). J Am Coll Cardiol 1995; 26:922-930.
18. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. J Am Coll Cardiol 1998;31:1518-1524.